Steven J ODay
Overview
Explore the profile of Steven J ODay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
14478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chand D, Savitsky D, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P, et al.
Cancer Discov
. 2024 Jul;
14(12):2407-2429.
PMID: 39083809
This study reveals that Fc-enhanced anti-CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti-CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a...
2.
Bullock A, Schlechter B, Fakih M, Tsimberidou A, Grossman J, Gordon M, et al.
Nat Med
. 2024 Jun;
30(9):2558-2567.
PMID: 38871975
Microsatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody...
3.
Rudin C, Pandha H, Zibelman M, Akerley W, Harrington K, Day D, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36669791
Background: Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors. Methods: Patients had advanced non-small cell...
4.
Silk A, ODay S, Kaufman H, Bryan J, Norrell J, Imbergamo C, et al.
Cancer Immunol Immunother
. 2022 Nov;
72(6):1405-1415.
PMID: 36445410
Background: CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937) + pembrolizumab for metastatic/unresectable stage IIIB-IV melanoma. Methods: Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3 weeks...
5.
DAgnillo F, Walters K, Xiao Y, Sheng Z, Scherler K, Park J, et al.
Sci Transl Med
. 2021 Oct;
13(620):eabj7790.
PMID: 34648357
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is characterized by respiratory distress, multiorgan dysfunction, and, in some cases, death. The pathological mechanisms underlying...
6.
Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, et al.
JAMA Oncol
. 2020 Jul;
6(8):1256-1264.
PMID: 32672795
Importance: The optimal sequencing of immune checkpoint inhibitors and targeted therapy for BRAF V600E/K-mutant melanoma is not well established. Objective: To assess the association of BRAF wild-type (WT) or BRAF...
7.
Arnaldez F, ODay S, Drake C, Fox B, Fu B, Urba W, et al.
J Immunother Cancer
. 2020 May;
8(1).
PMID: 32385146
The pandemic caused by the novel coronavirus SARS-CoV-2 has placed an unprecedented burden on healthcare systems around the world. In patients who experience severe disease, acute respiratory distress is often...
8.
Lin S, Chang S, Lam S, Ramos R, Tran K, Ohe S, et al.
Clin Chem
. 2019 Nov;
66(1):169-177.
PMID: 31672856
Background: Blood molecular profiling of circulating tumor cells (CTCs) can enable monitoring of patients with metastatic melanoma during checkpoint inhibitor immunotherapy (CII) and in combination with targeted therapies. We developed...
9.
Gangadhar T, Hwu W, Postow M, Hamid O, Daud A, Dronca R, et al.
J Immunother
. 2017 Oct;
40(9):334-340.
PMID: 29028788
KEYNOTE-030 (ClinicalTrials.gov ID, NCT02083484) was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with advanced melanoma before its regulatory approval. Patients...
10.
Amin A, Lawson D, Salama A, Koon H, Guthrie Jr T, Thomas S, et al.
J Immunother Cancer
. 2016 Aug;
4:44.
PMID: 27532019
Background: Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may preclude...